Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Apr 29;18(5):942. doi: 10.3390/ijms18050942

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

RE-CE attenuates IR-induced alterations in hematopoietic stem and progenitor cells (HSPCs) frequency. Mice were daily treated with the vehicle or 50 mg/kg RE-CE by gavage for 30 min before 4 Gy or 6 Gy TBI and up to 7 days after radiation. Mice were sham-irradiated as the control or CE group. (A) The number of BM cells (BMCs) per femur on the 14th day after exposure to 4 Gy or 6 Gy TBI; (B–D) The percentages of HSPCs were analyzed by FACS on the 14th day after exposure to 4 Gy or 6 Gy TBI; (B) The percentage of HPCs (hematopoietic progenitor cells, Lineage⁻sca1⁻c-kit⁺) among the lineage-negative cells; (C) The percentage of LSKs (Lineage⁻sca1⁺c-kit⁺) among the lineage-negative cells; (D) The percentage of CD34⁻LSKs among the LSK cells; (E) The percentage of CD34⁺LSKs among the LSK cells; (F) Representative FACS analyses of the percentage of HPCs, LSKs, CD34⁺LSKs, and CD34⁻LSKs; (G–J) The percentages of HSPCs analyzed by FACS 2 months after exposure to 6 Gy TBI; (G) The percentage of HPCs among lineage-negative cells; (H) The percentage of LSKs among lineage-negative cells; (I) The percentage of CD34⁻LSKs among LSK cells; (J) The percentage of CD34⁺LSKs among LSK cells. RE-CE treatment significantly increased the number of BMCs per femur, the frequencies of HPC, LSK, and CD34⁺LSK, and resulted in decreased frequencies of CD34⁻LSK. The data are presented as mean ± SEM (n = 5−15); ^# p < 0.05 vs. control; * p < 0.05 vs. 4 Gy.

RE-CE attenuates IR-induced alterations in hematopoietic stem and progenitor cells (HSPCs) frequency. Mice were daily treated with the vehicle or 50 mg/kg RE-CE by gavage for 30 min before 4 Gy or 6 Gy TBI and up to 7 days after radiation. Mice were sham-irradiated as the control or CE group. (A) The number of BM cells (BMCs) per femur on the 14th day after exposure to 4 Gy or 6 Gy TBI; (B–D) The percentages of HSPCs were analyzed by FACS on the 14th day after exposure to 4 Gy or 6 Gy TBI; (B) The percentage of HPCs (hematopoietic progenitor cells, Lineage⁻sca1⁻c-kit⁺) among the lineage-negative cells; (C) The percentage of LSKs (Lineage⁻sca1⁺c-kit⁺) among the lineage-negative cells; (D) The percentage of CD34⁻LSKs among the LSK cells; (E) The percentage of CD34⁺LSKs among the LSK cells; (F) Representative FACS analyses of the percentage of HPCs, LSKs, CD34⁺LSKs, and CD34⁻LSKs; (G–J) The percentages of HSPCs analyzed by FACS 2 months after exposure to 6 Gy TBI; (G) The percentage of HPCs among lineage-negative cells; (H) The percentage of LSKs among lineage-negative cells; (I) The percentage of CD34⁻LSKs among LSK cells; (J) The percentage of CD34⁺LSKs among LSK cells. RE-CE treatment significantly increased the number of BMCs per femur, the frequencies of HPC, LSK, and CD34⁺LSK, and resulted in decreased frequencies of CD34⁻LSK. The data are presented as mean ± SEM (n = 5−15); ^# p < 0.05 vs. control; * p < 0.05 vs. 4 Gy.